Novartis' Pluvicto has proven that radioligand therapy can become a genuine blockbuster — peak sales guidance now raised to $5B — triggering a big-pharma land-grab for isotope supply that has reshaped M&A in oncology.
📈 What changed: Lantheus' reported ~$7B Curium takeover talks remain unresolved as of July 23, 2026, nearly two months after Bloomberg's initial May 22 report — no definitive agreement has been a…
| Indicator | Score | Reading |
|---|---|---|
| Maturity higher is better · high confidence | 82/100 | Novartis' Pluvicto has proven radioligand therapy can become a genuine blockbuster, triggering a wave of big-pharma acquisitions racing to secure isotope supply. |
| Evidence Strength higher is better · high confidence | 61/100 | Multiple independent market-research houses and company financial disclosures corroborate the sector's commercial scale and growth trajectory. |
| Commercial Proximity higher is better · high confidence | 85/100 | A proven blockbuster product (Pluvicto) anchors real revenue, with a fast-growing challenger (Telix) eroding incumbent share. |
| Capital & Policy Support higher is better · high confidence | 61/100 | FDA accelerated pathways and Medicare payment reform provide real regulatory tailwinds specific to this modality, alongside heavy private biopharma investment. |
| Crowding Risk lower is better · medium confidence | 85/100 | Heavy big-pharma consolidation and rising valuations reflect a sector attracting serious institutional conviction, approaching crowded-trade territory. |
| Reflexivity Risk lower is better · high confidence | 50/100 | A mix of earnings-grounded big-pharma exposure (Novartis) and more speculative, differentiation-dependent pure-plays (Telix and emerging alpha-emitter platforms). |
Every indicator score is computed by the Northstar engine from analyst-set ordinal bands — never hand-written, never stored.
The public page is the summary (backed by 12 cited sources). Full briefing — company map, catalysts, native signals and sources — is inside the app.
Open in the appStart free →The Northstar Signal — what moved across all 350 themes and why, in your inbox. Free, no spam, one-click unsubscribe.